D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)
ID: 355242Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355242

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAS-24-242.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the D-START: Data Science Track Award for Research Transition (D/START), a federal grant aimed at supporting innovative research utilizing advanced data science techniques to address substance use and substance use disorders (SUD). This funding opportunity encourages applications from a diverse range of eligible applicants, particularly those from underrepresented groups, and emphasizes the importance of interdisciplinary collaboration in developing effective interventions. Grants of up to $100,000 per year for a maximum of two years are available for well-defined projects that explore novel methodologies, including machine learning, to enhance health outcomes. Interested applicants should note that the application deadlines span from October 2024 to August 2026, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAS-24-242-Full-Announcement.html
    PAS-24-242.html
    The National Institutes of Health (NIH) is offering a funding opportunity titled D-START: Data Science Track Award for Research Transition (D/START), which aims to support research applications utilizing advanced data science techniques for addressing issues related to substance use and substance use disorders (SUD). This small grant program is open to diverse applicants, particularly those from underrepresented groups, and encourages cross-disciplinary collaborations. A total of six to seven awards are expected, providing up to $100,000 per year for a maximum of two years for well-defined research projects. Applications should explore innovative methodologies, including machine learning, to enhance intervention accessibility and efficiency across various health contexts. The application deadlines are set between October 2024 and August 2026, with a focus on creating actionable insights from both new and existing data sources. The program strongly adheres to ethical research standards and requires compliance with NIH’s Data Management and Sharing Policy. This funding initiative highlights the government's commitment to advancing substance use research through innovative data strategies and emphasizes the importance of interdisciplinary approaches to solving pressing health challenges.
    Similar Opportunities
    D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering the D-START: Data Science Track Award for Research Transition (D/START) under the R03 Small Grant Program, aimed at funding projects that utilize advanced data science techniques to investigate substance use and substance use disorders (SUD). This opportunity encourages new and established researchers to apply innovative methodologies to address critical questions in addiction research, with a focus on small-scale projects that can provide preliminary data for larger studies. The program is particularly designed to foster collaborations from underrepresented groups in STEM and aims to expedite the development of robust research programs in addiction-related data science. Applicants can request budgets of up to $100,000 for a maximum of two years, with a total of six to seven awards available, amounting to $1 million per year for fiscal years 2025 to 2027. Interested parties should submit their applications electronically through Grants.gov by the closing date of September 7, 2027, and can direct inquiries to grantsinfo@nih.gov.
    Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Imaging - Science Track Award for Research Transition (I/START)" aimed at advancing neuroimaging methodologies relevant to substance use disorder (SUD) research. This program encourages both new and established investigators to conduct small "proof-of-concept" studies within a one-year project period, with a funding ceiling of $150,000. The initiative is designed to lower barriers for researchers in adopting advanced imaging techniques, thereby contributing to significant advancements in understanding and addressing substance use challenges. Interested applicants can find more information and application details at the provided link, with the application deadline set for January 7, 2028.
    Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Substance Use/Substance Use Disorder Dissertation Research Award (R36), aimed at supporting doctoral candidates for up to two years in their dissertation research related to substance use disorders. This grant, under the National Institute on Drug Abuse (NIDA), encourages applications from diverse backgrounds and focuses on advancing knowledge in prevention, diagnosis, and treatment of substance misuse and related health outcomes, excluding independent clinical trials. Eligible applicants can receive up to $50,000 per year for innovative research aligned with NIDA’s strategic plan, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data." This initiative invites applications that propose innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to investigate the etiology and epidemiology of substance use behaviors and related disorders, including HIV prevention and health service utilization. The program aims to leverage public datasets to enhance understanding of substance use trajectories and effective prevention strategies, particularly focusing on underrepresented populations and health disparities. A total funding commitment of $2 million is available for fiscal year 2026, with applications due by January 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)" to support doctoral candidates in completing their dissertation research projects related to substance use disorders. This funding initiative aims to enhance the pool of talented researchers in the field by providing grants of up to $50,000 per year for direct costs over a maximum of two years, with a focus on projects that align with the National Institute on Drug Abuse (NIDA) strategic priorities. Applications are particularly encouraged from individuals who can contribute to diversifying the research workforce, and interested candidates must submit their applications by October 16, 2023, or on February 16 and June 16, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data," aimed at supporting innovative analyses of existing datasets related to substance use behaviors, including alcohol, tobacco, and illicit drugs, and their connections to health outcomes such as HIV. This grant, classified as an R21 Clinical Trial Not Allowed, encourages applicants to utilize existing social science, behavioral, administrative, and neuroimaging data to enhance understanding of drug use behaviors, their consequences, and effective prevention and treatment strategies. A total of $2 million is available for projects over a two-year period, with individual application budgets capped at $275,000. Interested applicants must submit their proposals electronically through Grants.gov by December 3, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications that support a diverse range of preclinical and clinical projects, with the goal of advancing medication studies toward FDA approval, emphasizing the importance of innovative approaches to drug misuse and addiction treatment. Eligible applicants include a variety of institutions, such as higher education entities and community organizations, with funding available up to $5 million per year for projects lasting up to three years. Interested parties can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by August 11, 2025.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)" aimed at advancing the development of Digital Therapeutics (DTx) for treating Substance Use Disorders (SUDs). This initiative seeks to support the creation of safe and effective clinical-grade digital platforms that can deliver therapeutic treatments, particularly for conditions that currently lack FDA-approved medications. The funding mechanism involves a two-phase cooperative agreement, with the UG3 phase focusing on initial milestones and design testing for up to two years, followed by the UH3 phase, which can extend for an additional three years upon successful completion of the UG3 phase. Eligible applicants include a diverse range of organizations, such as educational institutions, tribal governments, and community-based organizations. The application process opens on February 26, 2024, with multiple deadlines extending through late 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.